About
Immuno-oncology Drugs
Areas of Focus
Categories
Biologics & BiopharmaceuticalBoston & New England
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
1,313
By Phase
PHASE1: 2PHASE1/PHASE2: 2
By Status
RECRUITING: 4
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06108479Lead Sponsor
Study of DF6215 in Patients with Advanced Solid Tumors
PHASE1Recruiting
255 participants
Started: Nov 28, 2023 · Completed: Dec 31, 2027
NCT05597839Lead Sponsor
Study of DF9001 in Patients With Advanced Solid Tumors
PHASE1/PHASE2Recruiting
242 participants
Started: Nov 15, 2022 · Completed: Nov 30, 2027
NCT04423029Lead Sponsor
A Study of DF6002 Alone and in Combination With Nivolumab
PHASE1Recruiting
438 participants
Started: Jul 13, 2020 · Completed: Nov 30, 2027
NCT04143711Lead Sponsor
Study of DF1001 in Patients with Advanced Solid Tumors
PHASE1/PHASE2Recruiting
378 participants
Started: Nov 11, 2019 · Completed: Dec 31, 2026
Locations (1)
Headquarters
Waltham, MA, United States
Map
Loading map...